血液CSF1与CXCL12是冠状动脉疾病的因果介质
研究采用孟德尔随机化方法,在ORIGIN试验参与者中筛选227种生物标志物的遗传决定因素,并结合CARDIoGRAM consortium的CAD遗传效应,发现CSF1和CXCL12是CAD的因果介质。CSF1每升高1个标准差,CAD风险增加18%(OR 1.18,95%CI 1.08-1.30,p=2.1×10-4),且与主要不良心血管事件风险增加16%相关(HR 1.16,95%CI 1.09-1.23,p<0.001)。CXCL12同样显示因果关联,并在UK Biobank中得到验证。
要点
- CSF1和CXCL12被鉴定为CAD的因果介质,支持炎症和巨噬细胞靶向预防策略。
- CSF1每升高1个标准差,CAD风险增加18%,MACE风险增加16%。
- 遗传预测的CSF1和CXCL12水平与UK Biobank中的CAD相关。
核心结论
- CSF1和CXCL12是人类CAD的因果介质。
研究设计与样本
- 孟德尔随机化研究,在ORIGIN试验参与者(N=4,147)中鉴定227种生物标志物的遗传决定因素,结合CARDIoGRAM consortium(60,801例CAD病例和123,504例对照)的CAD遗传效应。
主要发现
- 经多重假设检验校正后,6种生物标志物与CAD存在因果关联,其中CSF1和CXCL12为新发现。
- CSF1每升高1个标准差,CAD风险增加18%(OR 1.18,95%CI 1.08-1.30,p=2.1×10-4)。
- CSF1每升高1个标准差,主要不良心血管事件风险增加16%(HR 1.16,95%CI 1.09-1.23,p<0.001)。
- 遗传预测的CSF1和CXCL12水平与UK Biobank(n=343,735)中的CAD相关。
临床怎么用
- 支持靶向炎症过程尤其是巨噬细胞来预防CAD,与CANTOS试验结果一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Identification of biomarkers that cause coronary artery disease (CAD) has led to important advances in prevention and treatment. Epidemiological analyses have identified many biomarker-CAD relationships; however, these associations may arise from reverse causation and/or confounding and therefore may not represent true causal associations. Mendelian randomization (MR) analyses overcome these limitations. OBJECTIVES: This study sought to identify causal mediators of CAD through a comprehensive screen of 237 biomarkers using MR. METHODS: MR was performed by identifying genetic determinants of 227 biomarkers in ORIGIN (Outcome Reduction With Initial Glargine Intervention) trial participants (N = 4,147) and combining these with genetic effects on CAD from the CARDIoGRAM consortium (60,801 cases and 123,504 controls). Blood concentrations of novel biomarkers identified by MR were then tested for association with incident major adverse cardiovascular events in ORIGIN. RESULTS: Six biomarkers were found to be causally linked to CAD after adjustment for multiple hypothesis testing. The causal role of 4 of these is well documented, whereas macrophage colony-stimulating factor 1 (CSF1) and stromal cell-derived factor 1 (CXCL12) have not previously been reported, to the best of our knowledge. MR analysis predicted an 18% higher risk of CAD per SD increase in CSF1 (odds ratio: 1.18; 95% confidence interval: 1.08 to 1.30; p = 2.1 × 10-4) and epidemiological analysis identified a 16% higher risk of major adverse cardiovascular events per SD (hazard ratio: 1.16; 95% confidence interval: 1.09 to 1.23; p < 0.001). Elevated CXCL12 levels were also identified as a causal risk factor for CAD with consistent epidemiological results. Furthermore, genetically predicted CSF1 and CXCL12 levels were associated with CAD in the UK Biobank (n = 343,735). CONCLUSIONS: The study identified CSF1 and CXCL12 as causal mediators of CAD in humans. Understanding the mechanism by which these markers mediate CAD will provide novel insights into CAD and could lead to new approaches to prevention. These results support targeting inflammatory processes and macrophages, in particular, to prevent CAD, consistent with the recent CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study). (Outcome Reduction With Initial Glargine Intervention [ORIGIN]; NCT00069784).
引用
- Sjaarda J, Gerstein H, Chong M, et al. Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. J Am Coll Cardiol. 2018. PMID: 30012324. doi:10.1016/j.jacc.2018.04.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。